Skip to main content
MedPathMedPath Home
Clinical Trials/CTRI/2017/10/009959
CTRI/2017/10/009959
Recruiting
未知

Development of a mathematical model to predict the occurrence of recurrent grade 2 or grade 3 Hand Foot Skin Reaction requiring dose modification in patients with either metastatic Renal Cell Carcinoma or unresectable Hepato Cellular Carcinoma receiving standard dose of Sorafenib.

Terry Fox Tata Memorial Centre0 sites0 target enrollmentTBD
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
ConditionsHealth Condition 1: C649- Malignant neoplasm of unspecifiedkidney, except renal pelvisHealth Condition 2: null- Metastatic RCCNon Resectable HCC

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: C649- Malignant neoplasm of unspecifiedkidney, except renal pelvisHealth Condition 2: null- Metastatic RCCNon Resectable HCC
Sponsor
Terry Fox Tata Memorial Centre
Status
Recruiting
Last Updated
4 years ago
OverviewInvestigatorsEligibility CriteriaOutcomesSimilar Trials

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Observational

Investigators

Sponsor
Terry Fox Tata Memorial Centre

Eligibility Criteria

Inclusion Criteria

  • •Patients age \> 18 yrs
  • •1\.Gender: male/female
  • •2\.Patients with Metastatic Renal cell carcinoma
  • •or Advanced Hepatocellular Carcinoma.
  • •3\. Patients who are sorafenib naive or those
  • •who are already on sorafenib without
  • •recurrent grade 2 or grade 3 HFSR over a
  • •period of 8 weeks or more on standard dose of sorafenib.
  • •4\. ECOG status 0 to 2\.
  • •5\. Patients who are capable of providing written informed consent form

Exclusion Criteria

  • •1\. Patients simultaneously taking another anti\-
  • •cancer agent or combination of anti\-cancer agents known to cause hand foot syndrome
  • •2\.Patients with pre\-existing dermatological
  • •condition affecting the hands or feet
  • •3\.Patients with an active dermatological
  • •condition due to previous chemotherapy or
  • •biologic therapy affecting the hands

Outcomes

Primary Outcomes

Not specified

Similar Trials

Recruiting
Not Applicable
Development of prognostic model for predicting the effect of treatment and survival for elderly patients with gastric cancer using tools of comprehensive geriatric assessment : single center prospective observational studyNeoplasms
KCT0008586Asan Medical Center200
Recruiting
Not Applicable
Development and Evaluation of Predictive Model for Delirium following surgeryDiseases of the musculoskeletal system and connective tissue
KCT0007984Seoul National University Hospital500
Not yet recruiting
Not Applicable
Development and Accuracy of a Prediction Model for Acute Kidney Injury in Postoperative Cardiovascular Surgery PatientsPostoperative cardiovascular surgery patients
JPRN-UMIN000046526Yokohama City University200
Recruiting
Not Applicable
Development of a Mathematical Model to calculate the risk of delirium after Oncological SurgeriesDelirium
RBR-34m423bFundação Antônio prudente- Hospital A.C.Camargo cancer Center
Active, not recruiting
Not Applicable
The AUTOFLOW Study - using data to predict if oxygen levels in the brain and kidneys are likely to become low.Prevention of cerebral and renal desaturation in major non-cardiac surgery.Surgery
ISRCTN10141428York Teaching Hospital NHS Foundation Trust100